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Accepted 4 August 2011A retrospective review of medical charts was used to
compare the use of a half dose of leuplin depot (3.75 mg/vial;
Takeda, Osaka, Japan) in a long agonist protocol for in vitro
fertilization (IVF) (long protocol) with the conventional pill-
leupron-HMG/FSH short agonist protocol (short protocol).
From January 2008 through December 2010, our unit
completed 108 IVF case cycles (Table 1). The major variation
between cases is the protocol for ovulation stimulation. The
same personnel used the fixed protocol to perform oocyte
retrieval, fertilization, in vitro culture, and embryo transfer. In
the long, half-dose depot protocol (long protocol), a half dose
of leuplin depot was given during menstruation. Then, we
started 150e225 IU HMG (Menopur, Ferring GmbH, Kiel,
Germany)/FSH (Puregon, Merck Serono, Modugno, Italy) on
a Thursday 3e4 weeks later. Ovulation was induced with
a 10,000 IU ßHCG (5000 IU Pregnnyl; Organon, Oss, Holland)
i.m. injection when the two leading follicles were 16 mm
above. Oocyte retrieval was performed 34e39 hours later. We
performed fixed-length (6 cm) embryo transfer 3 days after
oocyte retrieval. For luteal support after oocyte retrieval, we
administered 4 mg/day estrade (2 mg estradiol valerate; Syn-
mosa, Taipei, Taiwan) and crinone 8% vaginal gel (Merck
Senoro). Additionally, 1500 IU HCG was administered at D3,
D6, and D9. A urine pregnancy test was administered 14 days
later. If the pregnancy test was positive, a vaginosonogram was
performed 2 weeks later. We defined clinical pregnancy as the
observation of a gestational sac inside the uterine cavity on the
vaginosonogram.
In our cases series, the cases that were administered the long
protocol achieved a relatively higher pregnancy rate, although
it was not statistically significant (39.28% for patients admin-
istered the long protocol vs. 28.75% for patients administered
the short protocol; 31.48% total pregnancy rate; p¼ 0.071).* Corresponding author. Number 57, Section 1st Tung-Mong Road, Tainan
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depot protocol (11.14 1.075 days for the long protocol vs.
9.55 1.25 days for the short protocol; p¼ 0.002). More
gonadotropin doses were required in the long depot protocol
(1799 IU for the long depot protocol vs. 1231 IU days for the
short protocol; p¼ 0.008). No significant differences were
observed in terms of the ovarian hyperstimulation rate, fertil-
ization rate, implantation rate, or abortion rate.
A previous comparative study reported that IVF using an
agonist achieved better clinical pregnancy and delivery rates
than IVF using an antagonist [1]. We stopped using an
antagonist protocol due to poor results 2 years ago, even
though the antagonist protocol required fewer injections. The
IVF treatment protocol is a stressful procedure for the patient
because of many factors, including the limited success rate,
the use of multiple injections, and high cost [2].
Administering leuplin depot using the long protocol began
in 1991 [3]. In the conventional long protocol that utilizes
a short-acting agonist, the patient needed to receive daily
injections or a nasal spray for 2 weeks before ovulation could
be induced [4,5]. In the long leuplin depot protocol, we
preferred depot injections because it simplified the treatment
protocol and improved patient compliance [6,7]. Considering
the success rate, we found that using the long protocol resulted
in a relatively higher pregnancy rate (39.28% for the long depot
protocol vs. 28.75% for the short protocol; 31.48% total
pregnancy rate; p¼ 0.071), although this result is not statisti-
cally significant. No significant differences were found in terms
of the fertilization rate, implantation rate, or abortion rate. Our
findings seem compatible with the previously reported meta-
analysis of the Cochrane database, which demonstrated the
superiority of the long protocol over the short and ultrashort
protocols for GnRH agonist use in IVF and GIFT [4,8].
However, due to the limitations of the review analysis and the
poor study structure of the reviewed cases, we plan to pool
more cases and conduct a stricter study protocol in order to
consolidate our findings in the future.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Descriptive retrospective analysis of 108 IVF cases, including the half-dose leuplin depot cycle and the short protocol cycle.
Leuplin depot Short Total p
Cases 28 80 108
Mean age (range) (y) 33.24 (26e41) 34.6 (23e43) 33.78 (23e43)
Etiology < 0.05
Tubal 16% 29%
Other, female 44% 24%
Male factor 16% 4%
Multiple 20% 28%
Unknown 4% 15%
HMG/FSH 1799 (1000e2600) 1231 (750e3325) 0.008
Time required to induction (d) 11.14 1.075 9.55 1.25 0.002
E2 (IU/L) 1394.3 2071 1952 0.087
P4 (pg/ml) 0.876 1.24 1.22 0.463
No. of oocytes retrieved 6.44 5.51 5.76 0.37
Fertilization rate 71.20% 74% 73% 0.565
Ovarian hyperstimulation syndrome rate 3.5% (1/28) 5% (4/80) 4.6% (5/108) 0.828
No. of transferred embryos 3.03 (0e4) 2.58 (0e4) 2.78 (0e4) 0.137
Pregnancy rate 39.28% 28.75% 31.48% 0.071
Implantation rate 21.9% 15.4% 16.8% 0.254
Abortion rate 18.18% 17.39% 17.64% 0.912
Live birth rate 32.14% 23.8% 25.9% > 0.05
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are associated with a longer period of stimulation (11.14 days
for the long protocol vs. 9.55 days for the short protocol;
p¼ 0.002) and higher doses of gonadotropin (1799 IU for long
protocol vs. 1231 IU for the short protocol), indicating that it
would cost NT$ 7000e9000 (US$ 240e310) more to perform
the long depot protocol with an agonist.
Regarding the possible adverse effects, we did not find
a significant difference in terms of the hyperstimulation rate
(3.5% for the long protocol vs. 5% for the short protocol) or
the abortion rate (18.18% for the long protocol vs. 17.64% for
the short protocol). We used a half dose of the agonist depot,
and none of the patients needed additional treatments for
hormone deprivation. It is possible that this is the fourth study
to report the use of a half dose or low dose of an agonist depot
for IVF [6,9,10]. The adequate dose of the agonist depot still
requires further elucidation.
Safety is an unavoidable issue that must be considered. To
date, no evidence has been found of increased risk of preg-
nancy wastage or teratogenicity in human pregnancies exposed
to long-acting agonists [11]. Considering the benefits of easy
handling and the high success rate, we conclude that using
a half dose of the agonist depot in the long protocol is a viable
procedure. However, the possible downsides of this procedure
should be explained to the patient during consultation.
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